151 results
8-K
EX-99.1
MRK
Merck & Co Inc
1 Aug 23
Merck Announces Second-Quarter 2023 Financial Results
6:46am
). In chronic cough, Merck received an acceptance from the FDA for the resubmission of the New Drug Application for gefapixant and assigned a target
8-K
EX-99.1
qxubez abviykr5
3 Feb 22
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
6:39am
8-K
EX-99.1
si2mb
29 Jul 21
Merck Announces Second-Quarter 2021 Financial Results
7:01am
8-K
EX-99.1
3z4jnv8f azgixbdn5
29 Apr 21
Merck Announces First-Quarter 2021 Financial Results
6:38am
8-K
EX-99.1
c22d8b u7eehya
4 Feb 21
Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
6:50am